Oncolytic virotherapy for oral squamous cell carcinoma using replication-competent viruses

Saito, Kengo; Shirasawa, Hiroshi; Isegawa, Naohisa; Shiiba, Masashi; Uzawa, Katsuhiro; Tanzawa, Hideki

doi:10.1016/j.oraloncology.2009.09.002

Cited by 16 publications

(24 citation statements)

References 81 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…SV has shown promise as an anticancer agent in several preclinical models (Tseng et al, 2004;Zhang et al, 2004;Saito et al, 2009;Huang et al, 2011;Granot and Meruelo, 2012); however, translation of these findings to use in the clinic could be hindered by its pathology, which manifests as Pogosta disease in humans.…”

Section: Discussionmentioning

confidence: 99%

“…In addition to these properties, SV replicates extremely rapidly, with daughter virions beginning to bud from infected cells within 4 hr of infection . Bearing these properties in mind, we find it unsurprising that SV has shown promise as anticancer agent in several animal models (Tseng et al, 2004;Zhang et al, 2004;Saito et al, 2009;Huang et al, 2011;Granot and Meruelo, 2012) and is being targeted for clinical translation.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Tissue-Specific Attenuation of Oncolytic Sindbis Virus Without Compromised Genetic Stability

Kueberuwa

Cawood

Tedcastle

et al. 2014

Human Gene Therapy Methods

View full text Add to dashboard Cite

Wild-type Sindbis virus (SV) shows promise as an oncolytic agent, although potential off-target replication is a safety concern. To remove possible pathology reflecting virus replication in liver, muscle, and/or hematopoietic cells, microRNA (miR)-response elements (MREs) to liver-specific miR122, muscle-specific miR133a and miR206, or hematopoietic-specific miR142-3p were inserted into the Sindbis viral genome. We compared the effectiveness of MREs in two distinct genomic locations and found better tissue-specific attenuation when they were inserted into the structural polyprotein coding region (up to 6000-fold selectivity with miR142-3p) rather than into the 3' untranslated region (up to 850-fold with miR142-3p). While this degree of tissue-specific attenuation may be effective for relieving pathology in vivo, genetic instability of RNA viruses raises concerns over the mutation or loss of MREs conferring safety. Genetically modified SVs containing a reporter transgene, used as a surrogate for virus replication, mutated quickly in vitro, losing 50% transgene sequence within 6.2 passages. Using a shorter insert containing MREs but no transgene, complete genetic stability was observed over at least 10 passages. We conclude that SV may be genetically modified to improve clinical properties, but attention must be paid to ensure that genetic stability is sufficient for intended applications.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Tissue-Specific Attenuation of Oncolytic Sindbis Virus Without Compromised Genetic Stability

Kueberuwa

Cawood

Tedcastle

et al. 2014

Human Gene Therapy Methods

View full text Add to dashboard Cite

show abstract

“…MYXV, RCNV and TANV have all demonstrated oncolytic activity in various preclinical models [4,11,12] and do not cause infection in normal human tissue with the exception of tanapox virus which can produce a localized, limited infection [12]. Although numerous investigators have studied a variety of oncolytic viruses including various strains of vaccinia virus [7,15,16], this is the first evaluation of a panel of poxviruses for the control of head and neck cancer.…”

Section: Discussionmentioning

confidence: 99%

Vaccinia Virus Outperforms a Panel of Other Poxviruses as a Potent Oncolytic Agent for the Control of Head and Neck Squamous Cell Carcinoma Cell Lines

Nichols

Yoo²,

Um³

et al. 2013

Intervirology

View full text Add to dashboard Cite

Background: Head and neck squamous cell carcinoma (HNSCC) is the fifth most common cancer worldwide. Existing therapies for advanced tumors have high failure rates and can have severe consequences in terms of pain, disfigurement, and poor speech and swallowing function. New treatment strategies are needed to improve outcomes for patients suffering with this disease and oncolytic viruses represent a promising approach. Methods: We infected six well-characterized HNSCC cell lines (Cal27, Detroit562, FaDu, SCC4, SCC15, SCC25), with increasing doses of a panel of poxviruses (including myxoma, vaccinia, raccoonpox and tanapox viruses) modified to express green fluorescence protein to determine which virus was the most effective oncolytic agent in cell-based assays. Results: While myxoma, raccoonpox and tanapox displayed differing efficacy in the panel of cell lines, vaccinia virus was the most potent of the tested poxviruses and was highly effective in controlling cell growth in all cell lines. Conclusion: Oncolytic poxviruses, particularly vaccinia virus, were effective in killing HNSCC in vitro and hold promise as potential treatments for patients with HNSCC.

show abstract

“…As an oncolytic virus, the favorable features of SINV include rapid production of high-titer virus, efficient infection of a variety of cancer cells, and a high RNA replication rate in the cytoplasm [11]. The preferable characteristics of SINV for cancer therapy might be attributed to the combination of favorable viral growth and the uncontrolled cell proliferation of cancer cells, including deregulation of the cell cycle.…”

Section: Introductionmentioning

confidence: 99%

Alteration of cell cycle progression by Sindbis virus infection

Saito

Isegawa

et al. 2015

Biochemical and Biophysical Research Communications

Self Cite

View full text Add to dashboard Cite

We examined the impact of Sindbis virus (SINV) infection on cell cycle progression in a cancer cell line, HeLa, and a non-cancerous cell line, Vero. Cell cycle analyses showed that SINV infection is able to alter the cell cycle progression in both HeLa and Vero cells, but differently, especially during the early stage of infection. SINV infection affected the expression of several cell cycle regulators (CDK4, CDK6, cyclin E, p21, cyclin A and cyclin B) in HeLa cells and caused HeLa cells to accumulate in S phase during the early stage of infection. Monitoring SINV replication in HeLa and Vero cells expressing cell cycle indicators revealed that SINV which infected HeLa cells during G1 phase preferred to proliferate during S/G2 phase, and the average time interval for viral replication was significantly shorter in both HeLa and Vero cells infected during G1 phase than in cells infected during S/G2 phase.

show abstract

Oncolytic virotherapy for oral squamous cell carcinoma using replication-competent viruses

Cited by 16 publications

References 81 publications

Tissue-Specific Attenuation of Oncolytic Sindbis Virus Without Compromised Genetic Stability

Tissue-Specific Attenuation of Oncolytic Sindbis Virus Without Compromised Genetic Stability

Vaccinia Virus Outperforms a Panel of Other Poxviruses as a Potent Oncolytic Agent for the Control of Head and Neck Squamous Cell Carcinoma Cell Lines

Alteration of cell cycle progression by Sindbis virus infection

Contact Info

Product

Resources

About